RU2016119116A - Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов - Google Patents
Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов Download PDFInfo
- Publication number
- RU2016119116A RU2016119116A RU2016119116A RU2016119116A RU2016119116A RU 2016119116 A RU2016119116 A RU 2016119116A RU 2016119116 A RU2016119116 A RU 2016119116A RU 2016119116 A RU2016119116 A RU 2016119116A RU 2016119116 A RU2016119116 A RU 2016119116A
- Authority
- RU
- Russia
- Prior art keywords
- hgf
- composition according
- composition
- preventing
- growth factor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 10
- 108010029485 Protein Isoforms Proteins 0.000 title claims 5
- 102000001708 Protein Isoforms Human genes 0.000 title claims 5
- 208000034189 Sclerosis Diseases 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 16
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 238000001476 gene delivery Methods 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Фармацевтическая композиция для предупреждения или лечения бокового амиотрофического склероза, содержащая в качестве активного ингредиента два или более изомеров фактора роста гепатоцитов (HGF) или полинуклеотид, кодирующий изомеры.
2. Композиция по п. 1, отличающаяся тем, что две или более изоформ HGF включают полноразмерный HGF (fIHGF) и делетированный вариант HGF (dHGF).
3. Композиция по п. 2, отличающаяся тем, что полноразмерный HGF включает последовательность аминокислот SEQ ID NO: 1, а делетированный вариант HGF включает последовательность аминокислот SEQ ID NO: 2.
4. Композиция по п. 1, отличающаяся тем, что две или более изоформ HGF закодированы раздельными последовательностями нуклеотидов.
5. Композиция по п. 1, отличающаяся тем, что две или более изоформ HGF закодированы одной последовательностью нуклеотидов.
6. Композиция по п. 1, отличающаяся тем, что полинуклеотид является депротеинизированной ДНК или содержится в системе доставки генов.
7. Композиция по п. 6, отличающаяся тем, что системой доставки генов является вектор.
8. Композиция по п. 7, отличающаяся тем, что вектор является плазмидой.
9. Композиция по п. 8, отличающаяся тем, что вектор является рСК.
10. Способ предупреждения или лечения бокового амиотрофического склероза, включающий введение млекопитающему композиции, содержащей в качестве активного ингредиента два или более изомеров фактора роста гепатоцитов (HGF) или полинуклеотид, кодирующий изомеры.
11. Способ по п. 10, отличающийся тем, что две или более изоформ HGF включают полноразмерный HGF (fIHGF) и делетированный вариант HGF (dHGF).
12. Способ по п. 11, отличающийся тем, что полноразмерный HGF включает последовательность аминокислот SEQ ID NO: 1, а делетированный вариант HGF включает последовательность аминокислот SEQ ID NO: 2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130126216 | 2013-10-22 | ||
| KR10-2013-0126216 | 2013-10-22 | ||
| KR1020140143377A KR101779775B1 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
| KR10-2014-0143377 | 2014-10-22 | ||
| PCT/KR2014/009971 WO2015060650A2 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016119116A true RU2016119116A (ru) | 2017-11-28 |
| RU2639582C2 RU2639582C2 (ru) | 2017-12-21 |
Family
ID=53386224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016119116A RU2639582C2 (ru) | 2013-10-22 | 2014-10-22 | Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10639351B2 (ru) |
| EP (1) | EP3061457B1 (ru) |
| JP (1) | JP6240337B2 (ru) |
| KR (2) | KR101779775B1 (ru) |
| CN (1) | CN105682676B (ru) |
| AU (1) | AU2014337870B2 (ru) |
| BR (1) | BR112016008267A2 (ru) |
| CA (1) | CA2926607C (ru) |
| ES (1) | ES2773305T3 (ru) |
| HK (1) | HK1219873A1 (ru) |
| MX (1) | MX2016005006A (ru) |
| RU (1) | RU2639582C2 (ru) |
| SG (1) | SG11201602452SA (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3046202B1 (fr) * | 2015-12-24 | 2017-12-29 | Snecma | Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs |
| WO2019132624A1 (ko) * | 2017-12-29 | 2019-07-04 | 주식회사 헬릭스미스 | 하이브리드 hgf 유전자가 도입된 aav(아데노-연관 바이러스) 벡터 |
| JP7380670B2 (ja) * | 2018-07-17 | 2023-11-15 | ヘリックスミス カンパニー， リミテッド | Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療 |
| CN110577954A (zh) * | 2019-10-12 | 2019-12-17 | 北京万福来生物技术有限责任公司 | 突变的肝细胞生长因子基因及其应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0255320A3 (en) | 1986-07-28 | 1989-09-06 | Genzyme Corporation | Production of proteins in myeloma cells |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
| US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| EP0539590B1 (en) | 1990-07-13 | 1999-03-31 | Snow Brand Milk Products Co., Ltd. | Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same |
| US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
| US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
| JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5652225A (en) | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
| US6143714A (en) | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
| WO2001034208A1 (en) | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| CA2230819C (en) | 1995-08-29 | 2009-04-14 | Sumitomo Pharmaceuticals Co., Ltd. | Medicament comprising hgf gene |
| US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| JP2002515065A (ja) | 1997-05-06 | 2002-05-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物 |
| WO1999036103A1 (en) | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
| JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
| US20040228834A1 (en) | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
| WO1999045775A1 (en) | 1998-03-09 | 1999-09-16 | St. Elizabeth's Medical Center | Compositions and methods for modulating vascularization |
| EP1555033A3 (en) | 1998-03-13 | 2005-08-17 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| US7276359B1 (en) | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| PT1061955E (pt) | 1998-03-13 | 2005-08-31 | Wyeth Corp | Composicao de polinucleotido, metodo de preparacao e sua utilizacao |
| WO2000007615A1 (fr) | 1998-08-05 | 2000-02-17 | Sumitomo Pharmacueticals Co., Ltd. | Preparations destinees a l'administration d'un facteur de croissance des hepatocytes |
| KR20000046969A (ko) | 1998-12-31 | 2000-07-25 | 이선경 | 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더 |
| DE60040383D1 (de) | 1999-10-29 | 2008-11-13 | Anges Mg Inc | Gentherapie für diabetische ischämie |
| AU6633801A (en) | 2000-06-27 | 2002-01-08 | Medgene Bioscience Inc | Medicinal compositions for angiogenic therapy |
| KR20030034177A (ko) | 2000-09-13 | 2003-05-01 | 쥬가이 세이야쿠 가부시키가이샤 | 허혈성 질환 치료제 |
| US20030176347A1 (en) | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
| JP5442173B2 (ja) | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
| CN1150035C (zh) | 2000-12-21 | 2004-05-19 | 中国人民解放军军事医学科学院放射医学研究所 | 一种重组质粒及其在疾病防治中的应用 |
| CA2433936A1 (en) | 2001-01-23 | 2002-08-22 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
| KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
| WO2008121719A1 (en) | 2007-03-30 | 2008-10-09 | The Cleveland Clinic Foundation | Method of treating ischemic disorders |
| AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| US20050164208A1 (en) | 2004-01-22 | 2005-07-28 | Paul Poulin | Storage of genetic information |
| KR100833612B1 (ko) | 2004-12-29 | 2008-05-30 | 에프씨비파미셀 주식회사 | 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물 |
| US20070059288A1 (en) | 2005-03-31 | 2007-03-15 | Dinsmore Jonathan H | Treatment for heart disease |
| US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
| KR20080082629A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 간세포 성장인자 인트론 융합 단백질 |
| WO2007132873A1 (ja) | 2006-05-17 | 2007-11-22 | Yoshiyuki Koyama | 核酸、オリゴ核酸、又はその誘導体導入用の凍結乾燥体 |
| WO2007142651A1 (en) | 2006-06-09 | 2007-12-13 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods and compositions for the treatment of neuropathy |
| JP5248519B2 (ja) | 2007-11-07 | 2013-07-31 | 小野薬品工業株式会社 | Ｓｄｆ−１を含有してなる徐放性組成物 |
| US20090202606A1 (en) | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
| MX2010010993A (es) | 2008-04-09 | 2010-11-05 | Viromed Co Ltd | Formulaciones liofilizadas de adn para expresion mejorada de adn de plasmido. |
| RU2413524C1 (ru) | 2009-07-31 | 2011-03-10 | Общество с ограниченной ответственностью "КриоЦентр" | Способ лечения психических и неврологических расстройств |
| RU2609631C2 (ru) | 2009-12-23 | 2017-02-02 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг |
| WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
| WO2013037521A1 (en) | 2011-09-16 | 2013-03-21 | Medical Research Council | Modified hgf-1k1 polypeptide |
| WO2013037520A1 (en) | 2011-09-16 | 2013-03-21 | Glaxo Group Limited | Modified hgf-1k1 polypeptide |
| JP2013129661A (ja) * | 2013-02-20 | 2013-07-04 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
-
2014
- 2014-10-22 BR BR112016008267A patent/BR112016008267A2/pt not_active Application Discontinuation
- 2014-10-22 SG SG11201602452SA patent/SG11201602452SA/en unknown
- 2014-10-22 RU RU2016119116A patent/RU2639582C2/ru active
- 2014-10-22 CA CA2926607A patent/CA2926607C/en active Active
- 2014-10-22 EP EP14856385.1A patent/EP3061457B1/en active Active
- 2014-10-22 MX MX2016005006A patent/MX2016005006A/es active IP Right Grant
- 2014-10-22 AU AU2014337870A patent/AU2014337870B2/en active Active
- 2014-10-22 KR KR1020140143377A patent/KR101779775B1/ko active IP Right Grant
- 2014-10-22 JP JP2016546724A patent/JP6240337B2/ja active Active
- 2014-10-22 US US15/030,999 patent/US10639351B2/en active Active
- 2014-10-22 ES ES14856385T patent/ES2773305T3/es active Active
- 2014-10-22 CN CN201480058075.3A patent/CN105682676B/zh active Active
-
2016
- 2016-07-06 HK HK16107864.0A patent/HK1219873A1/zh unknown
-
2017
- 2017-08-31 KR KR1020170110892A patent/KR101860452B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016534149A (ja) | 2016-11-04 |
| KR101860452B1 (ko) | 2018-05-24 |
| EP3061457A4 (en) | 2017-06-07 |
| KR20170104129A (ko) | 2017-09-14 |
| RU2639582C2 (ru) | 2017-12-21 |
| AU2014337870A1 (en) | 2016-05-05 |
| SG11201602452SA (en) | 2016-05-30 |
| EP3061457B1 (en) | 2020-01-22 |
| CA2926607A1 (en) | 2015-04-30 |
| JP6240337B2 (ja) | 2017-11-29 |
| US10639351B2 (en) | 2020-05-05 |
| KR101779775B1 (ko) | 2017-09-21 |
| CA2926607C (en) | 2018-10-23 |
| MX2016005006A (es) | 2016-07-14 |
| AU2014337870B2 (en) | 2019-11-28 |
| US20160250291A1 (en) | 2016-09-01 |
| EP3061457A2 (en) | 2016-08-31 |
| ES2773305T3 (es) | 2020-07-10 |
| HK1219873A1 (zh) | 2017-04-21 |
| KR20150047108A (ko) | 2015-05-04 |
| BR112016008267A2 (pt) | 2017-10-03 |
| CN105682676A (zh) | 2016-06-15 |
| CN105682676B (zh) | 2020-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| NZ627372A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| MX2017011004A (es) | Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida. | |
| TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
| AR105822A1 (es) | Análogos de insulina | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| RU2016119116A (ru) | Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов | |
| MX2016002934A (es) | Inclusion del exon 2 inducida por antisentido en la alfa-glucosidasa ácida. | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| EA201391394A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| NZ727516A (en) | Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor | |
| JP2013136622A5 (ru) | ||
| RU2014101547A (ru) | Апоптоз-индуцирующее средство | |
| MD4481C1 (ru) | Рекомбинантный герпесвирус Кои (KHV) и вакцина для профилактики заболевания, вызванного KHV | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| JP2015514115A5 (ru) | ||
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| WO2015108856A3 (en) | Methods for enhancing the delivery of active agents | |
| JP2017517561A5 (ru) | ||
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| MX2021011039A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. |